This is Pavas Mehra and we are here at
Pareto Securities' 10th annual healthcare
conference in Stockholm with me I have
Carl-Johan Dalsgaard CEO of Vicore Pharma
Welcome Carl-Johan thank you very much could
you please tell us a little bit more
about Vicore Pharma and the drugs that
you were working on currently
Vicore Pharma is a rare disease company
focusing on fibrotic lung disease and we
have two programs one is a orally given
anti fibrotic anti-inflammatory drug
called C 21 the other one is an directly
given amid that will reduce the coughs
symptom which is a debilitating symptom
in these diseases and you have the two
of the drugs one is called VP01 one and
one is VP02 could you give us some
context on those what are they focusing
on VPO1 is a small molecule that is
binding and activating a receptor called
angiotensin 2 receptor which means
that it will prevent and reduce
inflammation and fibrosis and it will
also open up the small vessels in the
tissues - to increase blood flow in
tissues all good for treating these
diseases and these are both phase one
drugs currently, is that
correct
the VP01 one has just right now completed
the phase one and we will report that
within short and we're ready to shoot
off into phase two trials one in IPF
idiopathic pulmonary fibrosis and one in
systemic sclerosis which will be more a
mechanistic study so it's not a
treatment study in that disease so if we
look out of an investor perspective
looking forward are there any news
flows or any potential triggers that the
investors can be on the lookout for you
have a change of listing I think from
Nasdaq First North to the Primary Main
Market yep
so that is one thing also the report of
the phase one study that we have just
behind us and we're just collecting all
the data I think will contain a lot of
interesting positive news around the
molecule we will start and apply for for
the phase 2 studies and we also have the
other program that is in its formulation
phase with
we'll also be opportunities for for good
news and of course the up listing is
going to be during this fall as well and
the readouts that you're discussing and
the applications going forward are they
all scheduled for second half of 2019
the ones that we have that I talked
about is yes scheduled for second half
for 2019 then of course a readout of
those sides will come 2021 thank you for
being here today
and they we're really looking forward to
following Vicore ahead thank you
thank you very much
